Cliquez sur le graphique pour visiter les articles correspondants
NASH BIOTECHS
An overview on NASH disease
and future treatments
Navigation du site[Passer]
- MAIN
- ENGLISH
- THE NASH WORLD
- NASH INTRODUCTION
- BIOTECHS TARGETING NASH
- NASH TREATMENT- MARKET FORECAST AND ANALYSIS
- POINTS OF VIEW
- HOW THE COVID19 IS SHAKING UP THE NASH WORLD
- FROM NAFLD TO MAFLD, LAST MOVES !
- 2019, THE NASH LANDSCAPE
- GENFIT POSSIBLES SCENARIOS
- WHAT IS THE IMPACT OF THE SELADELPAR MISADVENTURES ON THE PBC AND NASH MARKETS?
- WHY BIOTECHS TARGETING NASH COMMUNICATE MORE AND MORE ABOUT DIABETES?
- NO ! INTERMEDIATE RESULTS OF SELADELPAR IN NASH ARE NOT A FAILURE!
- CYMABAY RESULTS WERE PREDICTABLE AND COHERENTS WITH PPAR's KNOWN ACTION
- NASH MARKET! , WE SHOULD STAY REALISTIC
- NASH! AND NOW?
- OCALIVA INTERMEDIATE RESULTS OF PHASE 3, QUICK ANALYSIS
- GILEAD’s POSSIBLES STRATEGIES IN NASH (updated february 2019)
- ELAFIBRANOR AND THE NEW PERSPECTIVES OF PPARs IN METABOLIC DISEASES
- SOMETHING IS ROTTEN IN THE STATE OF NASH INDUCED FIBROSIS TRIALS
- LPCN 1144 RESULTS QUICK ANALYSIS
- ELAFIBRANOR AMAZING RESULTS IN PBC
- ELAFIBRANOR, A REFERENCE IN NASH, IGNORED BY INVESTORS BUT NOT BY SCIENTISTS.
- MGL-3196 RESULTS QUICK ANALYSIS
- MADRIGAL MGL-3196 RESULTS IN NASH SEEMS GOOD
- NASH! THE INTERIM COHORT RECRUITMENT NEEDED FOR CLINICAL TRIAL PHASE 3 HAS BEEN REACHED FOR THE TWO LEADERS
- NASH BIOTECHS ARE UNDER EVALUATED
- 2018, THE NASH LANDSCAPE
- BYZANTINES QUARRELS AN SEX OF ANGELS
- NASH TRIAL RECRUITMENT BASICS
- LAST LANDSCAPE FOR THE MOST ADVANCED COMPOUNDS IN NASH
- OCALIVA ! THE DOUBTS BEFORE PRESCRIPTION !
- FDA SAFETY ALERT ON OCALIVA IN PBC WILL UNDOUBTEDLY IMPACT NASH
- OCALIVA PATH IS GETTING THINNER BY THE DAY
- SEMAGLUTIDE PERSPECTIVES IN NASH
- NASH AND NAFLD, WHAT PREVALENCE AND COMORBIDITIES (updated the 22 Aug 2017)
- NASH ! THE INTENT TO TREAT POPULATION
- INTERCEPT CONTROL TRIAL, WHAT ELSE !
- IMMURON - INTERIM ANALYSIS RESULTS - ??? UPDATED
- GENFIT’S TEASING REVEALS MOVES
- NASH CLINICAL TRIAL RECRUITMENT IS A MESS FOR ALL LABS
- INTERCEPT ! CHOICE IS IN THE AIR
- FXR AGONISTS, POTENTIAL INDUCED HCC HIGHLIGHTED
- NASH - GENFIT- RUMORS AND TRUTHS March 2017
- REGENERATE, A BIG CHANGE REVEALING A BIG MESS !
- NASH - GENFIT- RUMORS AND TRUTHS
- CLINICAL TRIALS IN NASH AND PROBABILITY OF SUCCESS.
- GILEAD IN NASH, A SMOKE SCREEN?
- NASH ! COMBO’s ARE THE WAY
- BIOPSY IN QUESTION ! FALSE NEGATIVES - FALSE POSITIVES
- SIMTUZUMAB, AN ENIGM !
- ELAFIBRANOR IN PBC , WHY
- TARGETING FIBROSIS ALONE IS A NONSENSE
- DIAGNOSIS AND LAB STRATEGIES
- IN THEIR LAST REPORTS ON NASH , BLOOMBERG COMPARE APPLES AND ORANGES !
- COMMENTS ON THE PUBLICATION OF GOLDEN STUDY RESULTS
- ALLERGAN / TOBIRA DEAL REVEAL A HUGE GAP BETWEEN FINANCIAL ANALYSTS AND BIG PHARMAS FORECAST ON NASH MARKET
- NASH ! SLIDES WAR IS DECLARED!
- STATUS REPORT ON NASH (August 2016)
- NASH CLINICAL TRIAL PARTICULARISMS
- UPDATE ON THE RACE TO NASH MARKET
- COMMENTS ON THE 'FITZGERALD CANTOR' POSITION ON ICPT
- OCA AND THE LDL CHOLESTEROL !
- PHASE III ‘REGENERATE’ RECRUITMENT ! A REASON OF HOURS ?
- INTERCEPT PHARMA, PBC AND FDA
- GENFIT AND THE CONJUNCTION OF PLANETS(by Gery DIVRY)
- ELAFIBRANOR, NEW PERSPECTIVES ...
- A NICE ARTICLE ON NASH IN ‘NATURE'
- NASH ! TREATMENT’S STRATEGIES AND COMPETITION
- NASH INVESTOR CHOICE IN 2016
- TAKE THE BIG PICTURE FOR GENFIT
- NO DOUBT THAT GENFIT'S DRUG CURES NASH
- NEW NASH FINDING FOR GENFIT
- THE FUTURE OF INTERCEPT PHARMACEUTICAL IN NASH ? (by Gery DIVRY)
- THE NEW DEFINITION OF NASH STRIKE THE NASH PLAYERS (by Gery DIVRY)
- A SECOND ANALYSIS ON THE INTERCEPT PHASE 2 ON NASH IN JAPAN (by Gery DIVRY)
- WHAT WE LEARN FROM OCA'S FAILURE IN JAPAN
- INTERCEPT'S STUDY CURIOSITIES (by Gery DIVRY)
- WHY BIOTECH BUBBLE IS ECONOMIC NONSENSE
- THE PLUS OF BIOMARKERS
- GENFIT'S BIOMARKERS
- FGF21, A HORMONE MARKER FOR NASH RESPONDERS
- GENFIT PHASE 3 DESIGN
- A NASH BIOTECH INVESTOR FILTER (by Gery DIVRY)
- FRANCAIS
- NEWSLETTER
- CONTACT
- SITE MAP
WWW.NASHBIOTECHS.COM - Copyright G DIVRY 2015-2016 - Contact and TERMS OF USE